|
Canada-0-FreightForwarding Azienda Directories
|
Azienda News:
- An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of . . .
Liver test abnormalities were defined as the occurrence of any abnormal liver test above the upper limit of normal (ULN) during isavuconazole treatment whereas liver tests were normal before treatment
- Liver Necrosis in a Patient Receiving Isavuconazole: Making the Case . . .
None of the patient's concomitant medications, 3 of which are metabolized by CYP3A4, have been found to increase isavuconazole serum concentrations or cause liver toxicity
- Isavuconazole - an overview | ScienceDirect Topics
After 3 total months of isavuconazole administrations liver enzymes began to rise with AST and ALT peaking at 1500 and 1100 U L, respectively, and bilirubin at 19 mg dL
- Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02 . . .
Voriconazole, posaconazole, and isavuconazole all led to hepatocellular liver injury Voriconazole administration led to a peak alanine aminotransferase (ALT) value of 1,793 U L (normal range, 9–59 U L) After posaconazole and isavuconazole treatment, ALT rose over 500 U L
- An Overview of Isavuconazole Clinical Use: A Multicentre . . . - Springer
According to isavuconazole summary of product characteristics, the elevations in hepatic enzymes rarely required discontinuation of isavuconazole, but monitoring of hepatic enzymes should be considered, as clinically indicated [3]
- Isavuconazole: Mechanism of Action, Clinical Efficacy, and . . . - MDPI
Hepatotoxicity can occur with isavuconazole and liver enzymes should be monitored while on therapy Overall, this occurs to a lesser extent than with other commonly used triazoles
- Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship . . .
In one patient increased bilirubin and liver enzymes grade 1 were observed and in other patient a grade 2 liver enzymes increase was observed No patient discontinued treatment due to adverse effects
- Safety and effectiveness of isavuconazole in real-life non-neutropenic . . .
The most reported event was liver enzyme elevation (10, 4 2%) and gastrointestinal or visual disturbances (2, 0 8%) Only nine (3 8%) patients had isavuconazole withdrawn due to TEAE (mainly due to liver enzyme elevation)
- Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
Hepatotoxicity can occur with isavuconazole and liver enzymes should be monitored while on therapy Overall, this occurs to a lesser extent than with other commonly used triazoles
|
|